The Therapeutic Alliance in Psychedelic-Assisted Psychotherapy: A Novel Target for Research and Interventions

Psychedelic-assisted therapy (PAT) combines classic psychedelic compounds with structured psychotherapeutic support and has produced rapid, sustained improvements across several psychiatric conditions, including major depressive disorder, post-traumatic stress disorder, and substance use disorders. Kamilar-Britt and colleagues note that enthusiasm from media, investors, and researchers has outpaced clarity about the mechanisms that drive therapeutic benefit; much of the early scientific attention has focused on pharmacological and subjective acute effects of the drugs, while the psychotherapy components of PAT have received comparatively little empirical study. This article sets out to highlight the therapeutic alliance—the collaborative, goal-oriented bond between client and therapist—as a potentially important but under-examined contributor to outcomes in PAT. The authors review evidence from decades of psychotherapy research on the alliance, summarise the sparse direct PAT data, discuss measurement options, and offer practical implications for researchers and clinicians. Their stated aim is to argue that measuring and deliberately strengthening the alliance in PAT is feasible, inexpensive, and likely to advance understanding of mechanisms and improve clinical outcomes.

The extracted text presents a narrative, evidence-synthesis and position piece rather than a formal systematic review or meta-analysis. The authors draw on existing large-scale meta-analyses of the therapeutic alliance in psychotherapy, selected empirical studies of PAT that examined alliance, and relevant theoretical literature about mechanisms (including state versus trait conceptualisations of alliance). No explicit search strategy, eligibility criteria, or systematic study-selection procedures are reported in the extracted text. Where practical recommendations are given, the authors identify commonly used alliance instruments (notably the Working Alliance Inventory and the Barrett-Lennard Relationship Inventory), discuss their psychometric properties and short-form options, and outline assessment timing (preparatory, dosing, and integration sessions) and rater sources (client, therapist/guide, independent observer). They also describe potential analytic and design choices qualitatively (for example, repeated measurement across sessions and inclusion of blind observers) but do not present a formal statistical plan or prespecified analytic methods in the provided text.

Kamilar-Britt and colleagues synthesise prior meta-analytic findings showing a consistent, moderate association between therapeutic alliance and psychotherapy outcome across many studies. They report pooled correlations from multiple meta-analyses, with Pearson's r estimates clustering around r = 0.21–0.28 (examples given: r = 0.21, k = 100; r = 0.28, k = 190; r = 0.28, k = 295). To aid interpretation, the authors invoke the Binomial Effect Size Display: using the smallest reported correlation (r = 0.21) would translate, under certain assumptions, into 60.5% of clients with a strong alliance improving versus 39.5% with a weak alliance; the larger estimate (r = 0.28) yields approximately 64% versus 34%. The authors also review methodological critiques that have argued earlier estimates may be inflated by reciprocal associations between alliance and outcome, measurement error, or time-varying confounding; detrended statistical approaches can reduce effect-size estimates substantially. They present the state–trait model of alliance as a counterpoint: trait-like qualities in client and therapist plus session-specific (state) interactions both contribute to outcomes and may help reconcile differing estimates. Direct empirical data from PAT are described as very limited: the extracted text identifies only two relevant publications. In one randomised trial of psilocybin for depression, a stronger therapeutic alliance in the PAT arm predicted greater emotional breakthrough and mystical-type experiences and was associated with outcomes at a magnitude larger than typical meta-analytic estimates (reported r = 0.49); alliance did not predict outcome in the escitalopram comparator arm of the same trial. In a second experimental study manipulating therapist support in a meditation/well-being context, higher support produced better daily experiences, gratitude, and purpose. These findings are presented as preliminary but suggestive that alliance may play an important role specifically in PAT. On measurement and assessment, the authors recommend routine inclusion of alliance measures in PAT protocols. They highlight the Working Alliance Inventory (including a 12-item short form) and the Barrett-Lennard Relationship Inventory (with a developing 12-item short form) as instruments with acceptable psychometrics. The authors argue for collecting reports from multiple perspectives (client, therapist/guide, and independent observers blind to condition) because inter-rater correlations can be low; they note that repeated measurement across preparatory, dosing, and integration sessions is preferable to single pre/post assessments to capture the nonlinear dynamics of alliance. Practical concerns such as rater burden and reactivity are acknowledged, and the authors suggest that even a single well-timed observation would improve current practice although multiple ratings offer greater insight.

The authors interpret the assembled evidence to mean that the therapeutic alliance is a plausible and actionable target for both research and clinical practice in PAT. They contend that alliance effects observed in conventional psychotherapy are substantial enough to warrant routine measurement in PAT trials and that preliminary PAT data support this emphasis, particularly because alliance predicted outcomes in at least one psilocybin trial but not in a pharmacological comparator arm. Kamilar-Britt emphasises that the alliance could influence outcomes directly and indirectly (for instance, by moderating the effects of therapist competence) and that its unique state and trait components may be especially relevant given PAT's atypical format (long sessions, multiple clinicians present during dosing, and distinct preparatory and integration phases). Practical implications for researchers include adding simple alliance measures to protocols, using multiple raters where possible, and timing assessments across treatment stages to capture dynamics. For clinicians, the authors recommend enhancing routine behaviours that bolster alliance—establishing goal consensus, underscoring progress, focusing on present concerns, respecting client autonomy, listening attentively, and asking permission before intervening. They further advise supervision and fidelity checks to reduce drift from evidence-based behaviours. Key limitations acknowledged in the paper are the ongoing methodological debate about the true magnitude of the alliance–outcome association, the potential for statistical artefacts to inflate estimates, and the paucity of direct PAT-specific empirical work. The authors therefore call for more empirical studies to measure alliance in PAT and to test whether deliberate alliance-focused interventions improve outcomes.

Kamilar-Britt and colleagues conclude that despite widespread theoretical emphasis on the therapeutic alliance in discussions of PAT, empirical investigation specific to psychedelic contexts is very limited. They argue that measuring and enhancing the alliance is feasible and low-cost and could substantially improve mechanistic understanding and clinical outcomes. The authors issue a clear call for more research and routine inclusion of alliance measures in PAT studies, noting that modest investments in measurement and clinician training could yield meaningful advances in effectiveness and our ability to alleviate suffering.